AbbVie's ABBV-453 Study: A Potential Breakthrough in Multiple Myeloma Treatment

AbbVie is conducting a Phase 1/2 study to assess the safety and efficacy of ABBV-453, a BCL-2 inhibitor, in relapsed/refractory multiple myeloma patients. The study aims to determine the optimal dosage and impact of ABBV-453 alone or in combination with other antimyeloma agents. A successful outcome could positively impact AbbVie's stock performance and position the company favorably against competitors in the multiple myeloma treatment market.

Antengene Corporation Limited (SEHK: 6996.HK) has announced that the China National Medical Products Administration (NMPA) has approved XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This approval marks the third indication of XPOVIO® in China, following its previous inclusion in the National Reimbursement Drug List for other indications [1].

The approval is based on the results of the BENCH study, which demonstrated that the XVd regimen offers greater efficacy, longer progression-free survival (PFS), a longer duration of response (DOR), a higher objective response rate (ORR), and a trend of prolonged overall survival (OS) compared to the Vd regimen in Chinese patients with R/R MM [1]. Notably, the study also showed significant clinical benefits for elderly patients, validating XPOVIO® as a better treatment option for this patient population [1].

XPOVIO®, a selective XPO1 inhibitor, is the world's first approved orally-available, selective XPO1 inhibitor. It has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets, including the mainland of China, Taiwan market, Australia, Singapore, and South Korea [1]. The approval of XPOVIO® in China could further expand its market reach and potentially increase revenue for Antengene.

Meanwhile, AbbVie is conducting a Phase 1/2 study to assess the safety and efficacy of ABBV-453, a BCL-2 inhibitor, in relapsed/refractory multiple myeloma patients. The study aims to determine the optimal dosage and impact of ABBV-453 alone or in combination with other antimyeloma agents. A successful outcome could positively impact AbbVie's stock performance and position the company favorably against competitors in the multiple myeloma treatment market.

References:
[1] https://finance.yahoo.com/news/antengene-announces-xpovio-approved-china-104900939.html